[go: up one dir, main page]

WO2006123031A3 - Composition pharmaceutique comprenant un onguent oleagineux et de la vitamine d ou l’un de ses derives a l'etat solubilise - Google Patents

Composition pharmaceutique comprenant un onguent oleagineux et de la vitamine d ou l’un de ses derives a l'etat solubilise Download PDF

Info

Publication number
WO2006123031A3
WO2006123031A3 PCT/FR2006/000971 FR2006000971W WO2006123031A3 WO 2006123031 A3 WO2006123031 A3 WO 2006123031A3 FR 2006000971 W FR2006000971 W FR 2006000971W WO 2006123031 A3 WO2006123031 A3 WO 2006123031A3
Authority
WO
WIPO (PCT)
Prior art keywords
vitamin
derivatives
pharmaceutical composition
oleaginous ointment
solubilised form
Prior art date
Application number
PCT/FR2006/000971
Other languages
English (en)
Other versions
WO2006123031A2 (fr
Inventor
Nathalie Barthez
Sandrine Orsoni
Laurent Fredon
Original Assignee
Galderma Res & Dev
Nathalie Barthez
Sandrine Orsoni
Laurent Fredon
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Galderma Res & Dev, Nathalie Barthez, Sandrine Orsoni, Laurent Fredon filed Critical Galderma Res & Dev
Priority to JP2008511744A priority Critical patent/JP5079689B2/ja
Priority to CA002608383A priority patent/CA2608383A1/fr
Priority to AU2006248878A priority patent/AU2006248878A1/en
Priority to EP06764575A priority patent/EP1885374A2/fr
Priority to BRPI0612911-0A priority patent/BRPI0612911A2/pt
Publication of WO2006123031A2 publication Critical patent/WO2006123031A2/fr
Publication of WO2006123031A3 publication Critical patent/WO2006123031A3/fr
Priority to US11/984,392 priority patent/US20100286285A1/en

Links

Classifications

    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82B—NANOSTRUCTURES FORMED BY MANIPULATION OF INDIVIDUAL ATOMS, MOLECULES, OR LIMITED COLLECTIONS OF ATOMS OR MOLECULES AS DISCRETE UNITS; MANUFACTURE OR TREATMENT THEREOF
    • B82B3/00—Manufacture or treatment of nanostructures by manipulation of individual atoms or molecules, or limited collections of atoms or molecules as discrete units
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
    • A61K31/592—9,10-Secoergostane derivatives, e.g. ergocalciferol, i.e. vitamin D2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
    • A61K31/593—9,10-Secocholestane derivatives, e.g. cholecalciferol, i.e. vitamin D3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/08—Antiseborrheics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • H—ELECTRICITY
    • H01—ELECTRIC ELEMENTS
    • H01L—SEMICONDUCTOR DEVICES NOT COVERED BY CLASS H10
    • H01L21/00—Processes or apparatus adapted for the manufacture or treatment of semiconductor or solid state devices or of parts thereof
    • H01L21/02—Manufacture or treatment of semiconductor devices or of parts thereof
    • H01L21/04—Manufacture or treatment of semiconductor devices or of parts thereof the devices having potential barriers, e.g. a PN junction, depletion layer or carrier concentration layer
    • H01L21/18—Manufacture or treatment of semiconductor devices or of parts thereof the devices having potential barriers, e.g. a PN junction, depletion layer or carrier concentration layer the devices having semiconductor bodies comprising elements of Group IV of the Periodic Table or AIIIBV compounds with or without impurities, e.g. doping materials
    • H01L21/20—Deposition of semiconductor materials on a substrate, e.g. epitaxial growth solid phase epitaxy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Dermatology (AREA)
  • Immunology (AREA)
  • Nanotechnology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Manufacturing & Machinery (AREA)
  • Transplantation (AREA)
  • Physics & Mathematics (AREA)
  • Condensed Matter Physics & Semiconductors (AREA)
  • General Physics & Mathematics (AREA)
  • Computer Hardware Design (AREA)
  • Microelectronics & Electronic Packaging (AREA)
  • Power Engineering (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La présente invention concerne une composition pharmaceutique anhydre destinée au traitement du psoriasis et d'autres désordres cutanés, caractérisée en ce qu'elle comprend un onguent oléagineux et à titre de principe actif un composé choisi parmi la vitamine D et ses dérivés, ledit actif étant sous une forme solubilisée dans ladite composition.
PCT/FR2006/000971 2005-05-16 2006-04-28 Composition pharmaceutique comprenant un onguent oleagineux et de la vitamine d ou l’un de ses derives a l'etat solubilise WO2006123031A2 (fr)

Priority Applications (6)

Application Number Priority Date Filing Date Title
JP2008511744A JP5079689B2 (ja) 2005-05-16 2006-04-28 油性軟膏と可溶化された形態のビタミンｄまたはその誘導体とを含む薬剤組成物
CA002608383A CA2608383A1 (fr) 2005-05-16 2006-04-28 Composition pharmaceutique comprenant un onguent oleagineux et de la vitamine d ou l'un de ses derives a l'etat solubilise
AU2006248878A AU2006248878A1 (en) 2005-05-16 2006-04-28 Pharmaceutical composition comprising an oleaginous ointment and vitamin D or the derivatives thereof in solubilised form
EP06764575A EP1885374A2 (fr) 2005-05-16 2006-04-28 Composition pharmaceutique comprenant un onguent oleagineux et de la vitamine d ou ses derives a l'etat solubilise
BRPI0612911-0A BRPI0612911A2 (pt) 2005-05-16 2006-04-28 composição farmacêutica anidra, uso da vitamina d e uso da composição
US11/984,392 US20100286285A1 (en) 2005-05-16 2007-11-16 Pharmaceutical composition comprising oleaginous ointments and vitamin D or its derivatives in the solubilized state

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR0504889A FR2885527B1 (fr) 2005-05-16 2005-05-16 Composition pharmaceutique comprenant un onguent oleagineux et de la vitamine d ou ses derives a l'etat solubilise
FR05/04889 2005-05-16

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US11/984,392 Continuation US20100286285A1 (en) 2005-05-16 2007-11-16 Pharmaceutical composition comprising oleaginous ointments and vitamin D or its derivatives in the solubilized state

Publications (2)

Publication Number Publication Date
WO2006123031A2 WO2006123031A2 (fr) 2006-11-23
WO2006123031A3 true WO2006123031A3 (fr) 2006-12-28

Family

ID=35462160

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/FR2006/000971 WO2006123031A2 (fr) 2005-05-16 2006-04-28 Composition pharmaceutique comprenant un onguent oleagineux et de la vitamine d ou l’un de ses derives a l'etat solubilise

Country Status (10)

Country Link
US (1) US20100286285A1 (fr)
EP (1) EP1885374A2 (fr)
JP (1) JP5079689B2 (fr)
KR (1) KR20080007608A (fr)
CN (1) CN101175497A (fr)
AU (1) AU2006248878A1 (fr)
BR (1) BRPI0612911A2 (fr)
CA (1) CA2608383A1 (fr)
FR (1) FR2885527B1 (fr)
WO (1) WO2006123031A2 (fr)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5042209B2 (ja) 2005-03-24 2012-10-03 ノーラブズ エービー 酸化窒素による美容治療、前記治療を実施する装置、及びその製造方法
JP2008222662A (ja) * 2007-03-14 2008-09-25 Betafarma Spa アトピー性皮膚炎を処置する衛生用および化粧用の組成物
FR2931662B1 (fr) * 2008-05-30 2010-07-30 Galderma Res & Dev Nouvelles compositions depigmentantes sous forme d'une composition anhydre sans vaseline et sans elastomere comprenant un derive phenolique solubilise.
EP4249001A3 (fr) 2009-08-21 2023-11-29 Novan, Inc. Gels topiques
BR112014000178A2 (pt) 2011-07-05 2017-02-07 Novan Inc composições tópicas
CA2865526C (fr) * 2012-03-14 2020-06-23 Novan, Inc. Compositions pharmaceutiques liberant de l'oxyde nitrique
US9855211B2 (en) 2013-02-28 2018-01-02 Novan, Inc. Topical compositions and methods of using the same
KR102321169B1 (ko) 2013-08-08 2021-11-02 노반, 인크. 국소 조성물 및 그의 사용 방법
WO2016022170A1 (fr) 2014-08-08 2016-02-11 Novan, Inc. Émulsions topiques
WO2016126982A1 (fr) * 2015-02-05 2016-08-11 Marc Selner Suspension de nano-vésicules ioniques et biocide préparé à partir d'une telle suspension
WO2017151905A1 (fr) 2016-03-02 2017-09-08 Novan, Inc. Compositions destinées à traiter l'inflammation et méthodes de traitement associées
BR112018070578A2 (pt) 2016-04-13 2019-02-12 Novan, Inc. composições, sistemas, kits, e métodos para tratar uma infecção
CN106902075A (zh) * 2017-02-23 2017-06-30 任君刚 一种基于无水技术的水敏感粘附性软膏及其制备方法
EP3758679A4 (fr) 2018-03-01 2021-12-15 Novan, Inc. Suppositoires libérant de l'oxyde nitrique et leurs procédés d'utilisation

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4335120A (en) * 1979-03-21 1982-06-15 Hoffmann-La Roche Inc. Administration of biologically active vitamin D3 and vitamin D2 materials
US4871723A (en) * 1984-10-08 1989-10-03 Teijin, Limited Method for treating psoriasis by externally administering to a patient a pharmaceutical composition containing active-type vitamin D
WO2003050067A2 (fr) * 2001-12-10 2003-06-19 Galderma Research & Development, Snc Analogues de la vitamine d

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6226223A (ja) * 1985-07-25 1987-02-04 Teijin Ltd 乾癬治療剤
JP3506505B2 (ja) * 1994-09-27 2004-03-15 帝人株式会社 白斑治療剤
JPH08119865A (ja) * 1994-10-26 1996-05-14 Teijin Ltd 神経線維腫症治療剤
FR2761889B1 (fr) * 1997-04-11 1999-12-31 Oreal Patch pharmaceutique, cosmetique ou dermo-pharmaceutique pour la delivrance de plusieurs composes actifs de nature differente
WO2001003712A1 (fr) * 1999-07-09 2001-01-18 Astion Development Aps Composition contenant des extraits de butyrospermum parkii et utilisation en tant que medicament ou supplement alimentaire
US6924400B2 (en) * 2001-12-10 2005-08-02 Galderma Research & Development, Snc Triaromatic vitamin D analogues
US7060260B2 (en) * 2003-02-20 2006-06-13 E.I. Du Pont De Nemours And Company Water-soluble silk proteins in compositions for skin care, hair care or hair coloring
FR2871694B1 (fr) * 2004-06-17 2008-07-04 Galderma Sa Composition pharmaceutique comprenant un onguent oleagineux et deux principes actifs solubilises

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4335120A (en) * 1979-03-21 1982-06-15 Hoffmann-La Roche Inc. Administration of biologically active vitamin D3 and vitamin D2 materials
US4871723A (en) * 1984-10-08 1989-10-03 Teijin, Limited Method for treating psoriasis by externally administering to a patient a pharmaceutical composition containing active-type vitamin D
WO2003050067A2 (fr) * 2001-12-10 2003-06-19 Galderma Research & Development, Snc Analogues de la vitamine d

Also Published As

Publication number Publication date
AU2006248878A1 (en) 2006-11-23
EP1885374A2 (fr) 2008-02-13
CA2608383A1 (fr) 2006-11-23
BRPI0612911A2 (pt) 2010-12-07
JP2008540619A (ja) 2008-11-20
FR2885527A1 (fr) 2006-11-17
KR20080007608A (ko) 2008-01-22
CN101175497A (zh) 2008-05-07
US20100286285A1 (en) 2010-11-11
JP5079689B2 (ja) 2012-11-21
WO2006123031A2 (fr) 2006-11-23
FR2885527B1 (fr) 2007-06-29

Similar Documents

Publication Publication Date Title
WO2006123031A3 (fr) Composition pharmaceutique comprenant un onguent oleagineux et de la vitamine d ou l’un de ses derives a l'etat solubilise
WO2006120682A3 (fr) Compositions et methodes pour traiter des maladies epidermiques hyperproliferatives
WO2008011364A3 (fr) Compositions contenant de la quercétine
WO2008011363A3 (fr) Compositions contenant de la quercétine
WO2007046097A3 (fr) Compositions topiques pour le traitement ou la prevention de l'irritation cutanee provoquee par l'epilation
WO2008076754A3 (fr) Composés et compositions utilisés comme inhibiteurs de l'activité du récepteur cannabinoïde 1
WO2007092065A3 (fr) Composés et compositions servant de modulateurs du lxr
WO2006047516A3 (fr) Composes et compositions servant d'inhibiteurs d'activite de recepteur cannabinoide de type 1
WO2006102610A3 (fr) Composes bicycloheteroaryle utilises en tant que modulateurs de p2x7 et leurs utilisations
WO2006096439A3 (fr) Compositions pharmaceutiques destinees au traitement et/ou a la prevention de la schizophrenie et de maladies associees
WO2006099941A8 (fr) 8-n-benzimidazoles a substitution aminocarbonyle, leur procede de production, et leur utilisation en tant que medicaments
WO2007061661A3 (fr) Inhibiteurs de la 11-beta-hydroxy steroide deshydrogenase de type 1
DE60325379D1 (de) Zusammensetzung enthaltend 6-Ä3-(1-adamantyl)-4-methoxyphenylÜ-2-naphthanoesäure zur Behandlung dermatologischer Erkrankungen
WO2007068894A3 (fr) Nouveaux composes
ECSP066883A (es) Derivados de heteroarilaminopirazol utiles para el tratamiento de la diabetes
WO2007109279A3 (fr) Composes de tetrahydropyridothienopyrimidine et leurs procedes d'utilisation
WO2008073332A3 (fr) Compositions de créatine pour traitement cutané
WO2010007482A3 (fr) Dérivés de thiazole en tant qu’inhibiteurs de stéaroyl-coa désaturase
WO2009037542A3 (fr) Composés spirocycliques en tant qu'inhibiteurs de stéaroyle coa désaturase
WO2009084034A3 (fr) Dérivés de chromane utilisés comme modulateurs de trpv3
WO2008100621A3 (fr) Modulateurs de la cathepsine s au thioéther de tétrahydro-pyrazolo-pyridine
WO2005077122A3 (fr) Composes et compositions convenant comme modulateurs des lxr
WO2005102296A3 (fr) Associations pour traiter des troubles cutanes immunoproliferatifs
WO2010004379A3 (fr) Dérivés du chromane comme modulateurs de trpv3
WO2008100622A3 (fr) Modulateurs de la cathepsine s à la tétrahydro-pyrazolo-pyridine substituée par un biaryle

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2006764575

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: MX/A/2007/014075

Country of ref document: MX

WWE Wipo information: entry into national phase

Ref document number: 2608383

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2008511744

Country of ref document: JP

Ref document number: 200680016725.3

Country of ref document: CN

Ref document number: 1020077026645

Country of ref document: KR

WWE Wipo information: entry into national phase

Ref document number: 8854/DELNP/2007

Country of ref document: IN

NENP Non-entry into the national phase

Ref country code: DE

WWW Wipo information: withdrawn in national office

Ref document number: DE

WWE Wipo information: entry into national phase

Ref document number: 2006248878

Country of ref document: AU

WWP Wipo information: published in national office

Ref document number: 2006248878

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2007146707

Country of ref document: RU

WWP Wipo information: published in national office

Ref document number: 2006764575

Country of ref document: EP

ENP Entry into the national phase

Ref document number: PI0612911

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20071030